Document:

<PAGE>

                                                                   EXHIBIT 10.14

                                                                           LONZA

                                 AMENDMENT NO. 1

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              dated 08 January 2004

                                     between

                               LONZA BIOLOGICS PLC

                                       and

                          TRUBION PHARMACEUTICALS, INC.

Re:

Schedule 2 -- Services

New Stage

     Add Stage 15 Development Pilot Batch (non-cGMP) at *** Scale

Schedule 3 -- Price and Payment

     Price and Payment for Stage 15

                                                          CONFIDENTIAL TREATMENT

<PAGE>

                                                                           LONZA

THIS AMENDMENT is made the 4th day of June 2004

BETWEEN

1.   LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road,
     Slough, Berkshire SL1 4DX, England ("LB") and

2.   TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
     98121, USA (herein after referred to as the "Customer").

WHEREAS

A.   Customer and LB entered into a development and manufacturing services
     agreement dated 08 January 2004 ("the Agreement'), under which LB is
     required to perform Services relating to the Cell Line and the Product, as
     further described in the Agreement, and

B.   Customer would like LB to perform additional services under the Agreement,
     and

C.   LB is prepared to perform the additional services, and the parties wish to
     amend the Agreement accordingly.

NOW THEREFORE it is agreed hereby as follows:

1.   Schedule 2 of the Agreement shall be amended to include the following
     additional stage, Stage 15 (Development Pilot Batch (non-cGMP) at ***
     Scale):

                                   SCHEDULE 2

15   STAGE 15 -- Development Pilot Batch (non-cGMP) at *** Scale

     15.1 OBJECTIVES

          ***

     15.2 ACTIVITIES

          -    ***.

     15.3 TIMESCALE

          This Stage will commence any time after:

          -    the *** is available for use, and/or;

          -    sufficient information is available from Stages 1 and 3 of the
               Services to proceed.

                                                          CONFIDENTIAL TREATMENT

                                      -2-

<PAGE>

                                                                           LONZA

     This Stage shall be complete upon issue of the summary report to the
     Customer. It is estimated that this report shall be issued *** from
     commencement of this Stage.

2.   Schedule 3 of the Agreement shall be amended by the addition of the
     following provisions in respect of the additional Stages contained in this
     Amendment No. 1:

                                   SCHEDULE 3

                           Price and Terms of Payment

1.   Price

     In consideration for LB carrying out the Services described in Stage 15 as
     detailed in Schedule 2 the Customer shall pay LB as follows:

     STAGE ***

     Stage 15 Development Pilot Batch (non-cGMP) at *** Scale ***

2.   Payment

     Payment by the Customer of the Price for Stage 15 shall be made against
     LB's invoices as follows:

     2.1  For Stage 15

          *** upon commencement of Stage 15.

          *** upon completion of Stage 15.

3.   Any capitalized term used but not defined in this Amendment No. 1 shall
     have the meaning given in the Agreement.

4.   Save as herein provided all other terms and conditions of the Agreement
     shall remain in full force and effect.

                                                          CONFIDENTIAL TREATMENT

                                      -3-

<PAGE>

                                                                           LONZA

     IN WITNESS WHEREOF the parties have caused this Amendment No. 1 to be
executed by their duly authorised representatives thereunto as of the day and
year first above written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                     /s/ Rene Imwinkleried
                                        ----------------------------------------
                                        Director
                                        TITLE

Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC.           /s/ Kendall Mohler
                                        ----------------------------------------
                                        SVP, R&D
                                        TITLE

                                                          CONFIDENTIAL TREATMENT

                                      -4-<PAGE>

                                                                   EXHIBIT 10.15

                                                                           Lonza

                                 AMENDMENT NO. 2

                                       TO

              THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

                              DATED 08 JANUARY 2004

                                     BETWEEN

                               LONZA BIOLOGICS PLC

                                       AND

                          TRUBION PHARMACEUTICALS INC.

Re:

Schedule 2 - Services

Updated Stages

     Stage 1 Fermentation Process Evaluation
     Stage 2 ***
     Stage 8 ***

Schedule 2 - Services

New Stages

     Add Stage 16 ***
     Add Stage 17 ***
     Add Stage 18 ***

Schedule 3 - Price and Payment

Updated Price and Payment Terms for Updated Stages and New Stages

                                                          CONFIDENTIAL TREATMENT

<PAGE>

                                                                           Lonza

THIS AMENDMENT is made the 20 day July 2004

BETWEEN

1.   LONZA BIOLOGICS PLC, the registered office of which is at 228 Bath Road,
     Slough, Berkshire SL1 4DX, England ("LB") and

2.   TRUBION PHARMACEUTICALS, INC., of 2401 4th Avenue, Suite 1050, Seattle, WA
     98121, USA (herein after referred to as the "Customer").

WHEREAS

A.   Customer and LB entered into a development and manufacturing services
     agreement dated 08 January 2004 ("the Agreement"), under which LB is
     required to perform Services relating to the Cell Line and the Product, as
     further described in the Agreement, and

B.   Customer would like LB to perform additional services under the Agreement,
     and

C.   LB is prepared to perform the additional services, and the parties wish to
     amend the Agreement accordingly and to make other revisions to the
     Agreement.

NOW THEREFORE it is agreed as follows:

     1. Amendments to Schedule 2, Stages 1, 2 and 8. Schedule 2 of the Agreement
shall be amended to revise Stage 1 (Fermentation Process Evaluation), Stage 2
*** and Stage 8 (Production of *** of cGMP Product at *** Scale), as follows:

          1.1  Stage 1 of Schedule 2 shall now read In its entirety as follows:

STAGE 1 FERMENTATION PROCESS EVALUATION

     1.1  OBJECTIVES

     ***

     1.2  ACTIVITIES

     ***

     1.3  DELIVERABLES

               1.3.1 A report of activities for the shake flask and lab scale
     fermenter activities.

               1.3.2 A report of activities performed during virus testing of
     the ***.

                                                          CONFIDENTIAL TREATMENT

<PAGE>

     1.4  TIMESCALE

     This stage may start upon creation of the *** Cell Line and receipt of the
*** Cell Line from the Customer. This stage shall be complete upon issue of the
report for the virus testing activities.

     It is estimated that this stage shall be complete *** from commencement.

     1.2  Stage 2 of Schedule 2 shall now read In its entirety as follows:

STAGE 2 ***

     2.1  OBJECTIVES

     ***

     2.2  ACTIVITIES

     ***

     2.3  DELIVERABLES

               2.3.1 A report of activities carried out under this Stage 2 as
     detailed in activity 2.2.6.

               2.3.2 A one (1) page summary report to the customer for each
     ampoule revival during the *** (activity 2.2.5).

     2.4  TIMESCALE

     Stage 2 may commence as soon as the selected PSS is available from Stage 1
of the Services.

     Stage 2 shall be complete with the issue of the report (activity 2.3.1) and
it is estimated that this report will be issued *** from the commencement of
Stage 2.

     It is estimated that the *** will be established *** from the commencement
of Stage 2.

                                                          CONFIDENTIAL TREATMENT

                                       -2-

<PAGE>

     1.3  Stage 8 of Schedule 2 shall now read in its entirety as follows:

STAGE 8 ***

     8.1  OBJECTIVES

          ***

     8.2  ACTIVITIES

          ***

     8.3  DELIVERABLES

          ***

     8.4  TIMESCALE

     When the Customer and LB agree to the commencement of this Stage, this
stage may commence as soon as the *** is available for use and the Process
development activities and cGMP documents are complete.

     This stage shall be complete upon issue of the certificate of analysis for
the Batch of Product.

     It is estimated that Product will be delivered *** from commencement of the
Stage. If Customer requests in writing, the Product can be shipped in quarantine
prior to release. It is estimated that this shipment could occur *** from
commencement of the Stage.

                                                          CONFIDENTIAL TREATMENT

                                       -3-

<PAGE>

     2. Amendments to Schedule 2, Stages 16, 17, and 18. Schedule 2 of the
Agreement shall be amended to include the following additional stages, Stage 16
*** Testing for Adventitious Agents, Stage 17 (Cell Culture (***) Evaluation and
Stage 18 (Cell Culture *** Evaluation):

          2.1  A new Stage 16 shall be added to Schedule 2 of the Agreement and
               shall read in its entirety as follows:

STAGE 16 ***

     16.1 OBJECTIVES

               16.1.1 To carry out additional testing on the *** as instructed
     by the Customer.

     16.2 ACTIVITIES

               ***

     16.3 DELIVERABLES

               16.3.1 Issue a copy of the Testing Laboratory reports including
     description of materials and methods to the Customer containing the results
     of the tests carried out in 16.2.1.

     16.4 TIMESCALE

     This Stage may commence as soon as the *** is available from Stage 2 and
upon signature of this Amendment 2. This Stage shall be complete upon issue of
the Testing Laboratory reports (activity 16.2.1) and it is estimated that these
reports shall be issued *** from commencement of this Stage.

                                                          CONFIDENTIAL TREATMENT

                                       -4-

<PAGE>

     2.2 A new Stage 17 shall be added to Schedule 2 of the Agreement and shall
read in its entirety as follows:

STAGE 17 ***

     17.1 OBJECTIVES

          ***

     17.2 ACTIVITIES

          ***

     17.3 DELIVERABLES

               17.3.1 A report of activities carried out under this Stage 17 as
     detailed in activity 17.2.1,***.

     17.4 TIMESCALE

     Stage 17 may commence as soon as the *** is available from Stage 1 of the
Services.

     Stage 17 shall be complete with the issue of the report of activities and
it is estimated that this report will be issued *** from the commencement of
Stage 17.

                                                          CONFIDENTIAL TREATMENT

                                       -5-

<PAGE>

     2.3 A new Stage 18 shall be added to Schedule 2 of the Agreement and shall
read in its entirety as follows:

STAGE 18 ***

     18.1 OBJECTIVES

          ***

     18.2 ACTIVITIES

          ***

     18.3 DELIVERABLES

               18.3.1 A report of activities carried out under this Stage 18.

     18.4 TIMESCALE

     Stage 18 may commence as soon as the *** is available from Stage 2 of the
Services.

     Stage 18 shall be complete with the issue of the report of activities and
it is estimated that this report will be issued *** from the commencement of
Stage 18.

                                                          CONFIDENTIAL TREATMENT

                                       -6-

<PAGE>

     3. Amendments to Schedule 3. Schedule 3 of the Agreement shall be amended
to revise the price and terms of payment for Stages 1, 2 and 8, and to set forth
the price and payment terms for the additional Stages contained in this
Amendment No. 2, as follows:

                                   SCHEDULE 3

                           Price and Terms of Payment

1.   Price

     In consideration for LB carrying out the updated Services described in
Stage 1, Stage 2 and Stage 8; and the new Services as described in Stage 16,
Stage 17 and Stage 18, all as detailed in Schedule 2 as amended by this
Amendment No. 2, the Customer shall pay LB as set forth below, and Schedule 3 of
the Agreement shall be amended accordingly:

<TABLE>
<CAPTION>
STAGE      PRICE                             (***)
--------   -------------------------------   -----------------------------------
<S>        <C>                               <C>
Stage 1    Fermentation Process Evaluation   Price remains at ***
Stage 2    ***                               Price remains at ***
Stage 8    ***                               ***
Stage 16   ***                               Testing Laboratory charges actually
                                             incurred by LB plus ***
                                             administration charge, with total
                                             cost (charges plus mark-up)
                                             estimated to be***.
Stage 17   ***                               ***
Stage 18   ***                               ***
</TABLE>

2.   Payment

Payment by the Customer of the Price for each Stage shall be made against LB's
invoices as follows:

2.1  For Stage 1

     *** upon completion of Stage 1.

2.2  For Stage 2

     *** upon completion of Stage 2.

2.3  For Stage 8

     *** upon removal of an ampoule of *** out of freeze.

     *** upon issue of a Certificate of Analysis.

2.4  For Stage 16

     Testing Laboratory charges actually incurred by LB plus *** administration
charge, with *** payable upon completion of Stage 16.

2.5  For Stage 17

     No charge to the Customer

                                                          CONFIDENTIAL TREATMENT

                                       -7-

<PAGE>

2.6  For Stage 18
     No charge to the Customer

4. Amendment to Clause 3.3 of the Agreement. In the first line of Clause 3.3 of
the Agreement, the words "The parties agree that the *** Batches of Product
manufactured under Stage 8..." shall be replaced by "The parties agree that the
Batch of Product manufactured under Stage 8...", and any subsequent references
to 'Batches' in Clause 3.3 shall be changed to 'Batch'.

5. Approval to Use of ***. In accordance with Clause 3.8 of the Agreement, the
Customer hereby gives its written approval to the use of *** as a Testing
Laboratory.

6. Defined Terms. Any capitalized term used but not defined in this Amendment
No. 2 shall have the meaning given in the Agreement.

7. Full Force and Effect. Save as herein provided all other terms and conditions
of the Agreement shall remain in full force and effect.

     IN WITNESS WHEREOF the parties have caused this Amendment No 2 to be
executed by their duly authorised representatives thereunto as of the day and
year first above written.

Signed for and on behalf of
LONZA BIOLOGICS PLC                     /s/ Rene Imwinkleried
                                        ----------------------------------------
                                        Director
                                        Title
Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC.           /s/ Peter A. Thompson
                                        ----------------------------------------
                                        President & CEO
                                        Title

                                                          CONFIDENTIAL TREATMENT

                                       -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]